High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics.
The pharmaceutical industry faces a number of challenges that have cumulatively led to a decline in productivity, despite increasing levels of investment in research and development. It is in this context that some researchers and business analysts are questioning the value of the high-throughput screening (HTS) paradigm for the discovery of new therapeutics. While this criticism may be premature, significant changes are occurring in HTS-driven lead discovery to address the failure of drug candidates in the clinic. This article highlights some of these changes and their potential impact.
Posner
Bruce A
BA
Pfizer Global Research and Development, New Leads Biology: Exploratory Medicinal Sciences, Groton Laboratories, MS-8118W-110, Eastern Point Road, Groton,CT 06340, USA. bruce.a.posner@pfizer.com
D020650:Combinatorial Chemistry Techniques; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D008967:Molecular Biology